Evidence map›Paper›PMID 37142461›Full record

ArticleVaccine2023

COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.

Miao Jiang, Elina Väisänen, Pekka Kolehmainen, Moona Huttunen, Seppo Ylä-Herttuala, Seppo Meri, Pamela Österlund, Ilkka Julkunen

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Cytokine Profiles in Peripheral Blood Mononuclear Cells and Neutrophils following SARS-CoV-2 Vaccination: A Study from Kuwait.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Miao JiangExpert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare, 00300 Helsinki, Finland; Infection and Immunity, Institute of Biomedicine, University of Turku, 20520 Turku, Finland. Electronic address: miao.jiang@helsinki.fi.
Elina VäisänenExpert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare, 00300 Helsinki, Finland; Infection and Immunity, Institute of Biomedicine, University of Turku, 20520 Turku, Finland. Electronic address: elina.vaisanen@thl.fi.
Pekka KolehmainenInfection and Immunity, Institute of Biomedicine, University of Turku, 20520 Turku, Finland. Electronic address: pekka.j.kolehmainen@utu.fi.
Moona HuttunenInfection and Immunity, Institute of Biomedicine, University of Turku, 20520 Turku, Finland. Electronic address: moona.huttunen@utu.fi.
Seppo Ylä-HerttualaA.I.Virtanen Institute, Department of Molecular Medicine, University of Eastern Finland, 70210 Kuopio, Finland. Electronic address: seppo.ylaherttuala@uef.fi.
Seppo MeriDepartment of Bacteriology and Immunology and Translational Immunology Research Program, University of Helsinki, and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland. Electronic address: seppo.meri@helsinki.fi.
Pamela ÖsterlundExpert Microbiology Unit, Department of Health Security, Finnish Institute for Health and Welfare, 00300 Helsinki, Finland. Electronic address: pamela.osterlund@thl.fi.
Ilkka JulkunenInfection and Immunity, Institute of Biomedicine, University of Turku, 20520 Turku, Finland; Turku University Hospital, Clinical Microbiology, 20520 Turku, Finland. Electronic address: ilkka.julkunen@utu.fi.
University of Turku · FIFinnish Institute for Health and Welfare · FIUniversity of Eastern Finland · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring the COVID-19 pandemic multiple vaccines were rapidly developed and widely used throughout the world. At present there is very little information on COVID-19 vaccine interactions with primary human immune cells such as peripheral blood mononuclear cells (PBMCs), monocyte-derived macrophages and dendritic cells (moDCs).

methodsHuman PBMCs, macrophages and moDCs were stimulated with different COVID-19 vaccines, and the expression of interferon (IFN-λ1, IFN-α1), pro-inflammatory (IL-1β, IL-6, IL-8, IL-18, CXCL-4, CXCL-10, TNF-α) and Th1-type cytokine mRNAs (IL-2, IFN-γ) were analyzed by qPCR. In addition, the expression of vaccine induced spike (S) protein and antiviral molecules were studied in primary immune cells and in A549 lung epithelial cells.

resultsAdenovirus vector (Ad-vector) vaccine AZD1222 induced high levels of IFN-λ1, IFN-α1, CXCL-10, IL-6, and TNF-α mRNAs in PBMCs at early time points of stimulation while the expression of IFN-γ and IL-2 mRNA took place at later times. AZD1222 also induced IFN-λ1, CXCL-10 and IL-6 mRNA expression in monocyte-derived macrophages and DCs in a dose-dependent fashion. AZD1222 also activated the phosphorylation of IRF3 and induced MxA expression. BNT162b2 and mRNA-1273 mRNA vaccines failed to induce or induced very weak cytokine gene expression in all cell models. None of the vaccines enhanced the expression of CXCL-4. AZD1222 and mRNA-1273 vaccines induced high expression of S protein in all studied cells.

conclusionsAd-vector vaccine induces higher IFN and pro-inflammatory responses than the mRNA vaccines in human immune cells. This data shows that AZD1222 readily activates IFN and pro-inflammatory cytokine gene expression in PBMCs, macrophages and DCs, but fails to further enhance CXCL-4 mRNA expression.

Indexed as

COVID-19Vaccines2019-nCoV Vaccine mRNA-1273AdenoviridaeBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesCytokinesDendritic CellsHumansInterferonsInterleukin-2Interleukin-6Leukocytes, MononuclearMacrophagesmRNA Vaccines2019-nCoV Vaccine mRNA-1273BNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesCytokinesInterferonsInterleukin-2Interleukin-6mRNA VaccinesRNA, MessengerTumor Necrosis Factor-alphaVaccinesA549 cellsAdenovirus vector vaccineCOVID-19Human PBMCIFN responseMacrophagemoDCmRNA vaccinePro-inflammatory cytokines

Identifiers

PMID37142461
PMCPMC10126225
OpenAlexW4366992476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.